Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/1662
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | GOMEZ, David S. | |
dc.contributor.author | CAMPOS, Edvaldo V. | |
dc.contributor.author | AZEVEDO, Rodrigo P. de | |
dc.contributor.author | SILVA- JR., Joao Manoel da | |
dc.contributor.author | FERREIRA, Marcus C. | |
dc.contributor.author | SANCHES-GIRAUD, Cristina | |
dc.contributor.author | SILVA- JR., Carlindo Vieira | |
dc.contributor.author | SANTOS, Silvia R. C. J. | |
dc.date.accessioned | 2013-09-23T16:29:59Z | |
dc.date.available | 2013-09-23T16:29:59Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | BURNS, v.39, n.3, p.445-450, 2013 | |
dc.identifier.issn | 0305-4179 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/1662 | |
dc.description.abstract | Background: The objective of the study was to investigate vancomycin dose adjustment in pediatric burn patients by evaluating trough drug concentrations and the pharmacokinetic and pharmacodynamic (PK/PD) correlation. Methods: Study subjects included 13 patients who were 6.0 years old, 25 kg (median). with normal renal function. These had at least a 30% total burn surface area and inhalation injury were present in 7/13 patients. The patients were investigated prospectively. Plasma monitoring and PK assessments were performed by serial blood sample collections (30 sets). Only 0.2 mL of each plasma sample was required for our plasma measurements, which were made by high performance liquid chromatography. The vancomycin PK/PD target was set at AUC(0-24)(ss)/MIC > 400. Results: Trough values less than 10 mu g/mL were obtained in 16/30 sets (53%) as a consequence of increased plasma clearance and the apparent volume of distribution. The daily dose was subsequently increased from 43.4 +/- 9.0 mg/kg (mean +/- SD) to 98.0 +/- 17.9 mg/kg, p < 0.05. The PK/PD target was reached for pathogens with 0.5 mg/L, 1 mg/L, 2 mg/L and 4 mg/L MIC in 93.3% (28/30), 66.7% (20/30), 33.3% (10/30) and 3.3% (1/30) of the sets, respectively. Conclusions: To more rapidly achieve the PK/PD targets in pediatric burn patients with normal renal function, an initial dose of approximately 90-100 mg/kg/day is recommended; however, this higher dosage regimen should be further evaluated in this population in terms of efficacy and toxicity as well as in terms of achieving pharmacodynamic goals. | |
dc.description.sponsorship | CAPES | |
dc.description.sponsorship | FAPESP | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.relation.ispartof | Burns | |
dc.rights | restrictedAccess | |
dc.subject | Vancomycin | |
dc.subject | Dose adjustment | |
dc.subject | Trough | |
dc.subject | PK/PD correlation | |
dc.subject | Pediatric burn patients | |
dc.subject.other | care-unit patients | |
dc.subject.other | pharmacokinetics | |
dc.subject.other | population | |
dc.subject.other | antibiotics | |
dc.subject.other | plasma | |
dc.title | Individualised vancomycin doses for paediatric burn patients to achieve PK/PD targets | |
dc.type | article | |
dc.rights.holder | Copyright ELSEVIER SCI LTD | |
dc.identifier.doi | 10.1016/j.burns.2012.07.005 | |
dc.identifier.pmid | 22867735 | |
dc.subject.wos | Critical Care Medicine | |
dc.subject.wos | Dermatology | |
dc.subject.wos | Surgery | |
dc.type.category | original article | |
dc.type.version | publishedVersion | |
hcfmusp.author.external | AZEVEDO, Rodrigo P. de:Univ Sao Paulo, Hosp Clin, Sch Med, Plast Surg & Burns Div, Sao Paulo, Brazil | |
hcfmusp.author.external | SANCHES-GIRAUD, Cristina:Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil | |
hcfmusp.author.external | SILVA- JR., Carlindo Vieira:Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil | |
hcfmusp.author.external | SANTOS, Silvia R. C. J.:Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil | |
hcfmusp.description.beginpage | 445 | |
hcfmusp.description.endpage | 450 | |
hcfmusp.description.issue | 3 | |
hcfmusp.description.volume | 39 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | 2-s2.0-84875222734 | |
hcfmusp.origem.id | WOS:000317025500010 | |
hcfmusp.publisher.city | OXFORD | |
hcfmusp.publisher.country | ENGLAND | |
hcfmusp.relation.reference | Blanchet B, 2008, CLIN PHARMACOKINET, V47, P635, DOI 10.2165/00003088-200847100-00002 | |
hcfmusp.relation.reference | Bosso JA, 2011, ANTIMICROB AGENTS CH, V55, P5475, DOI 10.1128/AAC.00168-11 | |
hcfmusp.relation.reference | Branski LK, 2009, SURG INFECT, V10, P389, DOI 10.1089/sur.2009.024 | |
hcfmusp.relation.reference | Eiland LS, 2011, ANN PHARMACOTHER, V45, P582, DOI 10.1345/aph.1P588 | |
hcfmusp.relation.reference | Elligsen M, 2011, BURNS, V37, P406, DOI 10.1016/j.burns.2010.06.005 | |
hcfmusp.relation.reference | EUCAST. European Committee on Antimicrobial Susceptibility Testing, MIC DISTR | |
hcfmusp.relation.reference | FRYMOYER A, 2009, J PEDIAT INFECT DIS, V28, P398, DOI 10.1097/INF.0B013E3181906E40 | |
hcfmusp.relation.reference | GARRELTS JC, 1988, CLIN PHARMACOL THER, V44, P9 | |
hcfmusp.relation.reference | Giulano C, 2010, EXPERT REV ANTI-INFE, V8, P95, DOI [10.1586/eri.09.123, 10.1586/ERI.09.123] | |
hcfmusp.relation.reference | Glover ML, 2000, J CRIT CARE, V15, P1, DOI 10.1053/jcrc.2000.0150001 | |
hcfmusp.relation.reference | Greenhalgh DG, 2007, J BURN CARE RES, V28, P776, DOI 10.1097/BCR.0b013e3181599bc9 | |
hcfmusp.relation.reference | Kang Ju-Seop, 2009, Korean Journal of Internal Medicine, V24, P1, DOI 10.3904/kjim.2009.24.1.1 | |
hcfmusp.relation.reference | Lamarre P, 2000, ANTIMICROB AGENTS CH, V44, P278, DOI 10.1128/AAC.44.2.278-282.2000 | |
hcfmusp.relation.reference | Lopez KJV, 2007, J CHROMATOGR B, V860, P241, DOI 10.1016/j.jchromb.2007.10.041 | |
hcfmusp.relation.reference | Machado JK, 2007, CLINICS, V62, P405, DOI 10.1590/S1807-59322007000400006 | |
hcfmusp.relation.reference | Onishi A, 2005, DRUG METAB PHARMACOK, V20, P415 | |
hcfmusp.relation.reference | Reed JL, 2005, PEDIATR EMERG CARE, V21, P118, DOI 10.1097/01.pec.0000159058.95424.0d | |
hcfmusp.relation.reference | Reis A G, 1996, J Pediatr (Rio J), V72, P225 | |
hcfmusp.relation.reference | Revilla N, 2010, BRIT J CLIN PHARMACO, V70, P201, DOI 10.1111/j.1365-2125.2010.03679.x | |
hcfmusp.relation.reference | Roberts JA, 2009, CRIT CARE MED, V37, P840, DOI 10.1097/CCM.0b013e3181961bff | |
hcfmusp.relation.reference | RYBAK MJ, 1990, ANTIMICROB AGENTS CH, V34, P792 | |
hcfmusp.relation.reference | Rybak MJ, 2009, PHARMACOTHERAPY, V29, P1275 | |
hcfmusp.relation.reference | SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259 | |
hcfmusp.relation.reference | Soriano A, 2008, CLIN INFECT DIS, V46, P193, DOI 10.1086/524667 | |
hcfmusp.relation.reference | Weinbren MJ, 1999, J ANTIMICROB CHEMOTH, V44, P319, DOI 10.1093/jac/44.3.319 | |
hcfmusp.relation.reference | Wrishko RE, 2000, THER DRUG MONIT, V22, P522, DOI 10.1097/00007691-200010000-00004 | |
hcfmusp.relation.reference | Yang RH, 2009, BURNS, V35, P75, DOI 10.1016/j.burns.2008.05.016 | |
hcfmusp.relation.reference | Yasuhara M, 1998, THER DRUG MONIT, V20, P612, DOI 10.1097/00007691-199812000-00005 | |
dc.description.index | MEDLINE | |
hcfmusp.remissive.sponsorship | CAPES | |
hcfmusp.remissive.sponsorship | FAPESP | |
hcfmusp.citation.scopus | 19 | |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCG Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/04 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GOMEZ_Individualised_vancomycin_doses_for_paediatric_burn_patients_to_2013.PDF Restricted Access | publishedVersion (English) | 415.38 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.